|
pubmed:abstractText |
To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective.
|
|
pubmed:affiliation |
Departments of Surgery, Neurology, Pediatrics, Medicine, Radiation Oncology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina. vrede001@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
